Roche Pipeline Already Genentech-Loaded
This article was originally published in The Pink Sheet Daily
Candidates In Phase II And BeyondHow much of Genentech is in Roche's pipeline? Quite a bit. Of the 27 programs in Phase II development or later, one-third have their origins in Genentech's laboratories. Here's a summary of the crucial drugs and on-going clinical trials. (Source: Company websites)
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.
Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).